Generation of human IgG, IgA, and IgM anti-melanoma monoclonal antibodies utilizing lymphocytes of an actively immunized melanoma patient

Keyphrases

• Active Immunization 8%
• Allogeneic 16%
• Anti-melanoma 100%
• Associated Antigen 8%
• B Lymphocytes 8%
• Binding Antibodies 8%
• Cell Lysate 8%
• Colon 8%
• Diagnostic Applications 8%
• Human IgG 100%
• Human IgM 100%
• Human Immunoglobulin 8%
• Human Tumor Cells 8%
• Human Tumors 8%
• Humoral Immune Response 8%
• IgG2 33%
• Immunocytochemical Assay 8%
• Immunofluorescence Assay 8%
• Living Cells 8%
• Lung 8%
• Lymph Node Cells 8%
• Lymphocytes 100%
• Melanocytic Tumor 8%
• Melanoma 8%
• Melanoma Cells 16%
• Melanoma Patients 100%
• Melanoma Tumor Cells 25%
• Membrane-associated 8%
• Monoclonal Antibody 100%
• Pancreas 8%
• Permeabilized Cells 8%
• Prostate 8%
• Radioimmunoassay 8%
• Solid Phase 8%
• Splenocytes 8%
• Stronger Binding 8%
• Target Antigen 8%
• Therapeutic Use 8%
• Titer 8%
• Tumor Cell Lines 8%
• Tumor Cells 8%
• Western Immunoblotting 8%

Immunology and Microbiology

• B Cell 10%
• Binding Antibody 10%
• Cell Line 20%
• Cell Lysate 10%
• Colon 10%
• Human Immunoglobulin 10%
• Human Monoclonal Antibody 20%
• Humoral Immunity 10%
• Immunofluorescence 10%
• Immunoglobulin A 100%
• Immunoglobulin G2 40%
• Immunoglobulin M 100%
• Immunotherapy 20%
• Isotype 10%
• Lymph Node Cell 10%
• Lymphocyte 100%
• Melanoma Cell 20%
• Monoclonal Antibody 100%
• Pancreas 10%
• Radioimmunoassay 10%
• Splenocyte 10%
• Titer 10%
• Tumor Cell 40%
• Tumor Cell Line 10%
• Western Blot 10%